Chinook Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview

Chinook Therapeutics

02/11/2021 02:11

* Chinook Therapeutics Inc  KDNY.OQ   KDNY.O  is expected
to show a fall in quarterly revenue when it reports  results on
November 3 (estimated). 
* The Seattle, Washington-based company is expected to report  a
98.9% decrease in revenue to $41.67 thousand from $3.79 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Chinook Therapeutics
Inc is for a loss of 84 cents per share. For the same quarter
last year, the company reported a loss of 90 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Chinook
Therapeutics Inc is $32​, about 66.1% above​ its last closing
price of $10.84. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 302021   -0.79       -0.78      -1.14     Missed  -45.5
 Mar. 312021   -0.65       -0.68      -0.88     Missed  -30
 Dec. 312020   -0.51       -0.44      -1.24     Missed  -178.7
                                                        ​
 Sep. 302020   -0.49       -0.45      -0.90     Missed  -97.8
 ​​Jun.        -1.01       -0.95      -1.05     Missed  -10.5
 302020                                                 
 Mar. 312020   -0.76       -0.67      -0.45     Beat    33.3​
 Dec. 312019   -1.07       -1.05      -1.20     Missed  -13.9
 Sep. 302019   -1.17       -1.16      -1.00     Beat    13.7
 This summary was machine generated November 2 at 02:10 GMT.  All
figures in US dollars unless otherwise stated